Dallas plaintiffs lawyer Fred Baron is battling multiple myeloma, a blood cancer, and his physician is fighting a pharmaceutical company in an effort to use a medication to treat Baron’s illness that the Federal Drug Administration has not yet approved for that purpose.

News of Baron’s condition surfaced on Oct. 14 when Baron’s son Andrew posted a letter online that he had sent to James C. Mullen, the chief executive officer of Cambridge, Mass.-based Biogen Idec Inc. In the letter, Andrew Baron seeks to reverse Biogen’s decision to deny his father’s physician’s request to give Baron a medication that Andrew Baron argues could save his father’s life. Andrew Baron, the founder of New York City-based Rocketboom, did not respond to e-mail requests for comment.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]